Effect of Electro-Acupuncture on Blood Pressure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified October 2010 by University of California, Irvine.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

University of California, Irvine

ClinicalTrials.gov Identifier:

NCT00932139

First received: July 1, 2009

Last updated: October 14, 2010

Last verified: October 2010

History of Changes

Purpose

Based on previous published research in animals, the investigators hypothesize that electroacupuncture (EA) will have a positive effect on hypertension.

Condition	Intervention	Phase
Hypertension Arrhythmias	Procedure: Electro-acupuncture	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment
Official Title:	Neural Mechanism of the Effect of Acupuncture on Myocardial Ischemia

Resource links provided by NLM:

MedlinePlus related topics: Acupuncture

U.S. FDA Resources

Further study details as provided by University of California, Irvine:

Primary Outcome Measures:

Reduction in blood pressure [ Time Frame: 8 weeks ]

Secondary Outcome Measures:

Heart rate [ Time Frame: 8 weeks ]
Echocardiographic transthoracic output (CO) [ Time Frame: 8 weeks ]
Electrocardiogram (ECG) plasma catecholamines and renin [ Time Frame: 8 weeks ]


Estimated Enrollment:	94
Study Start Date:	February 2003
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Blood Pressure Acupuncture	Procedure: Electro-acupuncture First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heartrate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. Other Names: Blood pressure Hypertension Arrythmias

Detailed Description:

The purpose of this study is to prove: (1) Myocardial ischemia, cardiac arrhythmias and hypertensive response at rest and provoked by stress are decreased by EA; (2) The mechanism of the ischemic response is an imbalance between myocardial oxygen supply and demand originating as an increase in autonomic nervous system sympathetic activity causing increased oxygen demand. EA inhibits the sympathetic nervous system, decreases blood pressure and reduces the oxygen demand. Our prior data in animals shows that improvements in cardiovascular function during myocardial ischemia are mediated by an EA-induced sensory neural reflex originating in somatic nerves to reduce sympathetic nerve activity. The specific aims of the present study will allow us to better understand and modulate the sympathetic nervous discharge activity that can precipitate coronary ischemia, arrhythmias and hypertension in exercise stress in humans. Potential clinical application is the therapeutic value of EA in patients with hypertension.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with mild coronary disease, and no significant ECG change reflecting ischemia at rest

Exclusion Criteria:

Pregnant or nursing women
Individuals with severe coronary disease (continuous angina)
Conduction abnormalities on ECG consistent with left bundle branch block
Cardiac arrhythmias associated with low blood pressure (90 mmHg)
Peripheral vascular disease
Orthopedic disease
Diabetic or psychological illness that could interfere with safe performance of exercise of psychophysiological stress testing
Those with known sensitivity to topical preparations or strong reactions to medical dressings and skin tapes

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00932139

Contacts


Contact: Peng Li, MD, LAc	949-824-6123
Contact: Sivarama Prasad Vinjamury	562-947-8755 ext 7364

Locations


United States, California
General Clinical Research Center (GCRC)	Recruiting
Irvine, California, United States, 92697
Contact: Peng Li, MD, LAc 949-824-6123
Sub-Investigator: Peng Li, MD, LAc
Sub-Investigator: Sivarama Prasad Vinjamuary
Sub-Investigator: Eric Hsiao, MD, PhD

Sponsors and Collaborators

University of California, Irvine

Investigators


Study Director:	Peng Li, MD, LAc	University of California, Irvine
Study Director:	Sivarama Prasad Vinjamury	Southern California University of Health Sciences
Study Director:	Eric Hsiao, Md, PhD, LAc	Southern California University of Health Sciences

More Information


Responsible Party:	John C Longhurst, MD, PhD, University of California Irvine
ClinicalTrials.gov Identifier:	NCT00932139 History of Changes
Other Study ID Numbers:	1999-2222
Study First Received:	July 1, 2009
Last Updated:	October 14, 2010

Keywords provided by University of California, Irvine:


Hypertension blood pressure arrhythmias mild to moderate hypertension (145-199/90-110)

Additional relevant MeSH terms:


Hypertension Vascular Diseases Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top